GWAS identifies 15 gene variants responsible for diversity of white blood cell counts

NIH media availability

WHAT: A trio of large-scale genome-wide association studies, or GWAS, have identified more than 15 gene variants responsible for the diversity of white blood cell counts among whites, African-Americans, and Japanese. Supported in part by the National Institutes of Health, each study examined the genomes of tens of thousands of people. Combined, the studies offer the first comprehensive analysis into why some people, and some populations, have more or fewer white blood cells than others.

All three articles will be published online June 30 in PLoS Genetics.

White blood cells are part of the immune system, which fights infections and diseases. Measuring white blood cell levels is a common diagnostic test that can reveal underlying infections, cancers, or immune system disorders. Some scientific studies have also linked higher levels of white blood cells to increased risk of disease, including heart disease.

Some of the identified gene variants were responsible for altering total numbers of white blood cells, while other variants affected only one specific cell subtype, such as neutrophils, basophils, eosinophils, lymphocytes, and monocytes.

The findings could lead to important clinical advances. For example, these gene variants could be tested to pinpoint disease risks earlier in life. In addition, understanding the genetic basis behind altered white blood cell counts might also lead to gene therapies, such as boosting white blood cells in immune compromised people or reducing them in leukemia patients.

The National Heart, Lung, and Blood Institute, together with the National Institute on Aging, both part of the NIH, played key roles in the funding and design of both the white and African-American studies. The Institutes also worked closely with Japanese scientists to develop the third study.

WHO: Christopher O'Donnell, M.D., M.P.H., senior advisor to the NHLBI director for genome research and associate director of the NHLBI's Framingham Heart Study, which followed one of the population groups analyzed in these GWAS, and a co-author on all three articles, is available to comment on these findings and their clinical implications. Michael A. Nalls, Ph.D., in the NIA Laboratory of Neurogenetics and a co-author on all three papers is available to speak on how GWAS are making such discoveries possible.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Cell therapy improves outcomes for heart failure patients, clinical trial shows